ChiCTR2500098581 版本V1.0 版本创建时间2025/03/11 09:51:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500098581 

最近更新日期:

Date of Last Refreshed on:

2025-03-11 09:51:21 

注册时间:

Date of Registration:

2025-03-11 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

分段式液体管理方案对肝部分切除患者肾功能的影响

Public title:

Effect of segmented fluid management on renal function in patients with partial hepatectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

分段式液体管理方案对肝部分切除患者肾功能的影响

Scientific title:

Effect of segmented fluid management on renal function in patients with partial hepatectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐升 

研究负责人:

魏昕 

Applicant:

Xu Sheng 

Study leader:

Wei Xin 

申请注册联系人电话:

Applicant telephone:

+86 182 5678 4754

研究负责人电话:

Study leader's telephone:

+86 139 5697 5101

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2841984091@qq.com

研究负责人电子邮件:

Study leader's E-mail:

kekaiyuan628@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市庐江路17号

研究负责人通讯地址:

安徽省合肥市庐江路17号

Applicant address:

17 Lujiang Road, Hefei City, Anhui Province

Study leader's address:

17 Lujiang Road, Hefei City, Anhui Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

安徽省立医院

Applicant's institution:

Anhui Provincial Hospital

研究负责人所在单位:

安徽省立医院/中国科学技术大学附属第一医院

Affiliation of the Leader:

Anhui Provincial Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023KY伦审第067号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国科学技术大学附属第一医院医学研究伦理委员会

Name of the ethic committee:

Anhui Provincial Hospital Medical research Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2023-04-11 00:00:00

伦理委员会联系人:

沈佐君

Contact Name of the ethic committee:

Shen Zuojun

伦理委员会联系地址:

安徽省合肥市庐江路17号

Contact Address of the ethic committee:

17 Lujiang Road, Hefei City, Anhui Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 6228 2931

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

安徽省立医院/中国科学技术大学附属第一医院

Primary sponsor:

Anhui Provincial Hospital

研究实施负责(组长)单位地址:

安徽省立医院

Primary sponsor's address:

Anhui Provincial Hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

Country:

China

Province:

Anhui

City:

单位(医院):

安徽省立医院

具体地址:

安徽省合肥市庐江路17号

Institution
hospital:

Anhui Provincial Hospital

Address:

17 Lujiang Road, Hefei City, Anhui Province

经费或物资来源:

研究生课题

Source(s) of funding:

Graduate project

Target disease:

Space occupying lesion of live

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本项研究旨在比较分段式不同补液策略下对肝部分切除患者肾功能的影响。  

Objectives of Study:

The objective of this study was to compare the effects of different fractional fluid replenishment strategies on renal function in patients with partial hepatectomy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18~75岁,BMI 18-28kg/m^2 2.拟择期行肝部分切除的患者; 3.术前肝功能分级Child A~B级 4.美国麻醉医师协会(ASA)分级Ⅰ~III级 5.受试者阅读并充分理解患者须知,签署知情同意书。

Inclusion criteria

1. Age 18~75 years old, BMI 18-28kg/m^2 2. Patients who intend to undergo elective partial hepatic resection; 3. Preoperative liver function grading: Child A~B grade 4. American Society of Anesthesiologists (ASA) grade I.~III 5. The subject reads and fully understands the instructions for patients and signs the informed consent form.

排除标准:

1.严重心肺功能不全(中度以上瓣膜功能障碍,EF<60%,房颤,NYHA分级III~Ⅳ,中度以上阻塞性通气功能障碍) 2.术前肾功能异常(肌酐>133umol/L) 3. 凝血功能异常 4.存在其他研究者认为不适合纳入的情况

Exclusion criteria:

1. Severe cardiopulmonary insufficiency (moderate or above valvular dysfunction, EF<60%, atrial fibrillation, NYHA grade III~IV., moderate or above obstructive ventilatory dysfunction) 2. Abnormal renal function before surgery (creatinine >133umol/L) 3. Abnormal coagulation function 4. There are circumstances that other investigators consider unsuitable for inclusion

研究实施时间:

Study execute time:

From 2023-04-12 00:00:00 To 2024-06-26 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-12 00:00:00 To 2024-06-25 00:00:00  

干预措施:

Interventions:

组别:

目标导向液体平衡组

样本量:

88

Group:

Target directed liquid balance group

Sample size:

干预措施:

目标导向液体治疗组在肝脏占位切除后根据脉压变异率(pulse pressure variation,PPV)调整补液量,使得补液后PPV<=13%,如果PPV>13%,则在10min内输注250ml的6%的羟乙基淀粉液进行液体冲击,输注完毕后如果PPV<=13%,则只给予基础背景补液,若PPV仍旧大于13%,可以重复的250ml6%的羟乙基淀粉溶液进行液体冲击,如此循环操作

干预措施代码:

Intervention:

In the goal-directed fluid therapy group, the amount of fluid was adjusted according to the pulse pressure variation (PPV) after hepatic mass resection, so that the PPV < = 13% after fluid rehydration, if the PPV > 13%, 250ml of 6% hydroxyethyl starch solution was infused within 10 minutes for liquid shock, if PPV <=13% after infusion, only basal background rehydration was given, and if PPV was still greater than 13%, 250ml of 6% hydroxyethyl starch solution could be repeated for liquid shock, and so on

Intervention code:

组别:

液体零平衡组

样本量:

88

Group:

Liquid zero balance group

Sample size:

干预措施:

液体零平衡治疗组在肝脏占位切除后根据病人的体重计算生理需要量进行补液,在手术结束前补足病人的生理需要量和术中失血量及尿量,失血量按照1:2的胶体进行补充,尿量按照1:1的晶体液进行补充。

干预措施代码:

Intervention:

In the zero fluid balance treatment group, the physiological requirements were calculated according to the patient's body weight after liver space resection, and the physiological requirements, intraoperative blood loss and urine volume were supplemented before the end of the operation. The blood loss was supplemented according to 1:2 colloids, and the urine volume was supplemented according to 1:1 crystal fluid.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China 

Province:

Anhui  

City:

 

单位(医院):

安徽省立医院 

单位级别:

三甲 

Institution
hospital:

Anhui Provincial Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肾功能

指标类型:

主要指标

Outcome:

Renal Punction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血钾变化

指标类型:

次要指标

Outcome:

Potassium change

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后拔除气管导管时间

指标类型:

次要指标

Outcome:

Time of tracheal catheter removal after operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院天数

指标类型:

次要指标

Outcome:

Length of stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

Postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中出血量

指标类型:

次要指标

Outcome:

Intraoperative blood loss

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿量

指标类型:

次要指标

Outcome:

Urine volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由不参与本研究的人员,通过https://www.randomizer.org/生成随机数表,患者将根据生成的随机数表进行分组,单数为目标导向液体平衡组,双数为安液体零平衡组,组间分配比例为1:1。

Randomization Procedure (please state who generates the random number sequence and by what method):

By persons not involved in this study, via https://www.randomizer.org/ to generate random indicator, patients will be randomly generated according to the grouping meter, a singular goal oriented liquid balance group, dual zero balance for liquid group, group between the allocation ratio of 1:1.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲,对研究参与者和研究者设盲

Blinding:

Double-blind, blinding the study participants and investigators

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结果正式发表后,预计将2025年10月10日通过https://http://www.medresman.org.cn/共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After research results published, original data will be shared on October 10, 2025 by https://http://www.medresman.org.cn/.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-03-11 09:51:21